<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LITHIUM- lithium carbonate solution </strong><br>Precision Dose Inc.<br></p></div>
<h1>LITHIUM Oral Solution USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">R<span class="Sub">x </span>only</span></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-2"></a><p></p>
<h1><span class="Emphasis">WARNING</span></h1>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">Lithium toxicity</span> is closely related to serum lithium levels, and can occur at doses close to therapeutic levels. Facilities for prompt and accurate serum lithium determinations should be available before initiating therapy (see <a href="#dosageadmin">DOSAGE AND ADMINISTRATION</a>).</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<table class="Noautorules" width="100%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless">
<tr><td align="left" colspan="2">Each 5 mL of solution for oral administration contains:</td></tr>
<tr>
<td align="left">  Lithium ion (Li<span class="Sup">+</span>)</td>
<td align="left">8 mEq</td>
</tr>
<tr><td align="left" colspan="2">  (equivalent to amount of lithium in 300 mg of lithium carbonate), alcohol 0.3% v/v.</td></tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1"></a><p></p>
<h2>Inactive Ingredients</h2>
<p class="First">The solution contains citric acid, raspberry blend, sodium benzoate, sorbitol, and water.</p>
<p>Lithium Oral Solution is a palatable oral dosage form of lithium ion. It is prepared in solution from lithium hydroxide and citric acid in a ratio approximately dilithium citrate.</p>
<p>Lithium is an element of the alkali-metal group with atomic number 3, atomic weight 6.94, and an emission line at 671 nm on the flame photometer.</p>
<p>The empirical formula for Lithium Citrate is C<span class="Sub">6</span>H<span class="Sub">5</span>Li<span class="Sub">3</span>O<span class="Sub">7</span>; molecular weight 209.92. Lithium acts as an antimanic.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Preclinical studies have shown that lithium alters sodium transport in nerve and muscle cells and effects a shift toward intraneuronal metabolism of catecholamines, but the specific biochemical mechanism of lithium action in <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> is unknown.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Lithium is indicated in the treatment of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episodes</span> of Bipolar Disorder. Bipolar Disorder, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic</span> (DSM-III) is equivalent to <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Manic Depressive illness</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic</span>, in the older DSM-II terminology.</p>
<p>Lithium is also indicated as a maintenance treatment for individuals with a diagnosis of Bipolar Disorder. Maintenance therapy reduces the frequency of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episodes</span> and diminishes the intensity of those episodes which may occur.</p>
<p>Typical symptoms of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> include pressure of speech, motor <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>, reduced need for sleep, flight of ideas, grandiosity, elation, poor judgment, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span>, and possibly <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>. When given to a patient experiencing a <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episode</span>, lithium may produce a normalization of symptomatology within 1 to 3 weeks.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Lithium should generally not be given to patients with significant renal or cardiovascular disease, severe debilitation or <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, or <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">sodium depletion</span>, and to patients receiving diuretics, since the risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> is very high in such patients. If the psychiatric indication is life-threatening, and if such a patient fails to respond to other measures, lithium treatment may be undertaken with extreme caution, including daily serum lithium determinations and adjustment to the usually low doses ordinarily tolerated by these individuals. In such instances, hospitalization is a necessity.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="warnings"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">Lithium toxicity</span> is closely related to serum lithium levels, and can occur at doses close to therapeutic levels (see <span class="Bold"><a href="#dosageadmin">DOSAGE AND ADMINISTRATION</a></span>).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="unmask"></a><a name="section-6.1"></a><p></p>
<h2>Unmasking of <span class="product-label-link" type="condition" conceptid="4303408" conceptname="Brugada syndrome">Brugada Syndrome</span></h2>
<p class="First">There have been postmarketing reports of a possible association between treatment with lithium and the unmasking of <span class="product-label-link" type="condition" conceptid="4303408" conceptname="Brugada syndrome">Brugada Syndrome</span>. <span class="product-label-link" type="condition" conceptid="4303408" conceptname="Brugada syndrome">Brugada Syndrome</span> is a disorder characterized by abnormal electrocardiographic (ECG) findings and a risk of <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>. Lithium should generally be avoided in patients with <span class="product-label-link" type="condition" conceptid="4303408" conceptname="Brugada syndrome">Brugada Syndrome</span> or those suspected of having <span class="product-label-link" type="condition" conceptid="4303408" conceptname="Brugada syndrome">Brugada Syndrome</span>. Consultation with a cardiologist is recommended if: (1) treatment with lithium is under consideration for patients suspected of having <span class="product-label-link" type="condition" conceptid="4303408" conceptname="Brugada syndrome">Brugada Syndrome</span> or patients who have risk factors for <span class="product-label-link" type="condition" conceptid="4303408" conceptname="Brugada syndrome">Brugada Syndrome</span>, e.g., unexplained <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, a family history of <span class="product-label-link" type="condition" conceptid="4303408" conceptname="Brugada syndrome">Brugada Syndrome</span>, or a family history of sudden unexplained <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> before the age of 45 years, (2) patients who develop unexplained <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> or <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span> after starting lithium therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2>Pregnancy</h2>
<p class="First">Lithium may cause fetal harm when administered to a pregnant woman. There have been reports of lithium having adverse effects on nidations in rats, embryo viability in mice, and metabolism in-vitro of rat testis and human spermatozoa have been attributed to lithium, as have <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> in submammalian species and <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palates</span> in mice. Studies in rats, rabbits and monkeys have shown no evidence of lithium-induced teratology. Data from lithium birth registries suggest an increase in cardiac and other anomalies, especially Ebstein's anomaly. If the patient becomes pregnant while taking lithium, she should be apprised of the potential risk to the fetus. If possible, lithium should be withdrawn for at least the first trimester unless it is determined that this would seriously endanger the mother.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.3"></a><p></p>
<h2>Lithium-Induced Renal Effects</h2>
<p class="First">Chronic lithium therapy may be associated with diminution of renal concentrating ability, occasionally presenting as <span class="product-label-link" type="condition" conceptid="438476" conceptname="Nephrogenic diabetes insipidus">nephrogenic diabetes insipidus</span>, with <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span> and <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>. Such patients should be carefully managed to avoid <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> with resulting lithium retention and toxicity. This condition is usually reversible when lithium is discontinued.</p>
<p>Morphologic changes with glomerular and interstitial <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span> and nephron-<span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> have been reported in patients on chronic lithium therapy. Morphologic changes have also been seen in bipolar patients never exposed to lithium. The relationship between renal functional and morphologic changes and their association with lithium therapy has not been established.</p>
<p>When kidney function is assessed, for baseline data prior to starting lithium therapy or thereafter, routine urinalysis and other tests may be used to evaluate tubular function (e.g., urine specific gravity or <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> following a period of water deprivation, or 24-hour urine volume) and glomerular function (e.g., serum creatinine or creatinine clearance). During lithium therapy, progressive or sudden changes in renal function, even within the normal range, indicate the need for reevaluation of treatment.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="precautions"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">The ability to tolerate lithium is greater during the acute <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> phase and decreases when <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> symptoms subside (see <span class="Bold"><a href="#dosageadmin">DOSAGE AND ADMINISTRATION</a></span>).</p>
<p>The distribution space of lithium approximates that of total body water. Lithium is primarily excreted in urine with insignificant excretion in feces. Renal excretion of lithium is proportional to its plasma concentration. The half-life of elimination of lithium is approximately 24 hours. Lithium decreases sodium reabsorption by the renal tubules which could lead to <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">sodium depletion</span>. Therefore, it is essential for the patient to maintain a normal diet, including salt, and an adequate fluid intake (2500-3000 mL) at least during the initial stabilization period. Decreased tolerance to lithium has been reported to ensue from protracted <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and, if such occur, supplemental fluid and salt should be administered.</p>
<p>In addition to <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, concomitant <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with elevated temperatures may also necessitate a temporary reduction or cessation of medication.</p>
<p>Previously existing underlying <span class="product-label-link" type="condition" conceptid="141253" conceptname="Disorder of thyroid gland">thyroid disorders</span> do not necessarily constitute a contraindication to lithium treatment; where <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> exists, careful monitoring of thyroid function during lithium stabilization and maintenance allows for correction of changing thyroid parameters, if any. Where <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> occurs during lithium stabilization and maintenance, supplemental thyroid treatment may be used.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="per_infor"></a><a name="section-7.2"></a><p></p>
<h2>Information for the Patients</h2>
<p class="First">A condition known as <span class="product-label-link" type="condition" conceptid="4303408" conceptname="Brugada syndrome">Brugada Syndrome</span> may pre-exist and be unmasked by lithium therapy. <span class="product-label-link" type="condition" conceptid="4303408" conceptname="Brugada syndrome">Brugada Syndrome</span> is a <span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">heart disorder</span> characterized by abnormal electrocardiographic (ECG) findings and risk of <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>. Patients should be advised to seek immediate emergency assistance if they experience <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, abnormal heart beats, or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>.</p>
<p>Outpatients and their families should be warned that the patient must discontinue lithium therapy and contact his physician if such clinical signs of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> as <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, mild <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, or <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span> occur.</p>
<p>Lithium may impair mental and/or physical abilities. Caution patients about activities requiring alertness (e.g., operating vehicles or machinery).</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.1"></a><p></p>
<h3>Combined Use of Haloperidol and Lithium</h3>
<p class="First">An encephalopathic syndrome (characterized by <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremulousness</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span>, leucocytosis, elevated serum enzymes, BUN and FBS) followed by irreversible <span class="product-label-link" type="condition" conceptid="4080670" conceptname="Brain damage">brain damage</span> has occurred in a few patients treated with lithium plus haloperidol. A causal relationship between these events and the concomitant administration of lithium and haloperidol has not been established; however, patients receiving such combined therapy should be monitored closely for early evidence of neurological toxicity and treatment discontinued promptly if such signs appear.</p>
<p>The possibility of similar adverse interactions with other antipsychotic medication exists.</p>
<p>Lithium may prolong the effects of neuromuscular blocking agents. Therefore, neuromuscular blocking agents should be given with caution to patients receiving lithium.</p>
<p>Caution should be used when lithium and diuretics or angiotensin converting enzyme (ACE) inhibitors are used concomitantly because sodium loss may reduce the renal clearance of lithium and increase serum lithium levels with risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>. When such combinations are used, the lithium dosage may need to be decreased, and more frequent monitoring of lithium plasma levels is recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.2"></a><p></p>
<h3>Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)</h3>
<p class="First">Lithium levels should be closely monitored when patients initiate or discontinue NSAID use. In some cases, <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> has resulted from interactions between an NSAID and lithium. Indomethacin and piroxicam have been reported to increase significantly steady-state plasma lithium concentrations. There is also evidence that other nonsteroidal anti-inflammatory agents, including the selective cyclooxygenase-2 (COX-2) inhibitors, have the same effect. In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with celecoxib 200 mg BID as compared to subjects receiving lithium alone.</p>
</div>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.4"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.4.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4.1.1"></a><p></p>
<h4>Pregnancy Category D</h4>
<p class="First">See <span class="Bold"><a href="#warnings">WARNINGS</a></span> section.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.5"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Lithium is excreted in human milk. Nursing should not be undertaken during lithium therapy except in rare and unusual circumstances where, in the view of the physician, the potential benefits to the mother outweigh possible hazards to the child.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.6"></a><p></p>
<h2>Usage in Children</h2>
<p class="First">Since information regarding the safety and effectiveness of lithium in children under 12 years of age is not available, its use in such patients is not recommended at this time. There has been a report of a transient syndrome of <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">acute dystonia</span> and <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span> occurring in a 15 kg child who ingested 300 mg of lithium carbonate.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="adverse"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">Lithium Toxicity</span></h2>
<p class="First">The likelihood of toxicity increases with increasing serum lithium levels. Serum lithium levels greater than 1.5 mEq/l carry a greater risk than lower levels. However, patients sensitive to lithium may exhibit toxic signs at serum levels below 1.5 mEq/l.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span> and <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">lack of coordination</span> may be early signs of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>, and can occur at lithium levels below 2.0 mEq/l. At higher levels, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">giddiness</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span> and a large output of dilute urine may be seen. Serum lithium levels above 3.0 mEq/l may produce a complex clinical picture involving multiple organs and organ systems. Serum lithium levels should not be permitted to exceed 2.0 mEq/l during the acute treatment phase.</p>
<p>Fine hand <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span> and mild <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span> may occur during initial therapy for the acute <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> phase, and may persist throughout treatment. Transient and mild <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">general discomfort</span> may also appear during the first few days of lithium administration.</p>
<p>These side effects are an inconvenience rather than a disabling condition, and usually subside with continued treatment or a temporary reduction or cessation of dosage. If persistent, a cessation of dosage is indicated.</p>
<p>The following adverse reactions have been reported and do not appear to be directly related to serum lithium levels.</p>
<p><span class="Italics">Neuromuscular: </span><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span>, muscle hyperirritability (<span class="product-label-link" type="condition" conceptid="4189159" conceptname="Muscle fibrillation">fasciculations</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>, <span class="product-label-link" type="condition" conceptid="4270553" conceptname="Clonus">clonic movements</span> of whole limbs), <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, choreo-athetotic movements, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactive</span> deep tendon reflexes.</p>
<p><span class="Italics">Central Nervous System: </span><span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">Blackout spells</span>, epileptiform <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">incontinence of urine</span> or feces, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4160898" conceptname="Motor retardation">psychomotor retardation</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">acute dystonia</span>, downbeat <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>.</p>
<p><span class="Italics">Cardiovascular: </span><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Cardiac arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, peripheral <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, sinus node dysfunction with severe <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> (which may result in <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>), unmasking of <span class="product-label-link" type="condition" conceptid="4303408" conceptname="Brugada syndrome">Brugada Syndrome</span> (See <span class="Bold"><a href="#unmask">WARNINGS: Unmasking of <span class="product-label-link" type="condition" conceptid="4303408" conceptname="Brugada syndrome">Brugada Syndrome</span></a></span> and <span class="Bold"><a href="#per_infor">PRECAUTIONS: Information for the Patients</a></span>).</p>
<p><span class="Italics">Neurological: </span>Cases of <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span> (<span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span> and <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span>) have been reported with lithium use. If undetected, this condition may result in enlargement of the blind spot, constriction of visual fields and eventual <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span> due to <span class="product-label-link" type="condition" conceptid="372914" conceptname="Optic atrophy">optic atrophy</span>. Lithium should be discontinued, if clinically possible, if this syndrome occurs.</p>
<p><span class="Italics">Gastrointestinal: </span><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
<p><span class="Italics">Genitourinary: </span><span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">Albuminuria</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>.</p>
<p><span class="Italics">Dermatologic: </span>Drying and thinning of hair, anesthesia of skin, chronic <span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">folliculitis</span>, xerosis cutis, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> and <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">exacerbation of psoriasis</span>.</p>
<p><span class="Italics">Autonomic Nervous System: </span><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>.</p>
<p><span class="Italics">Thyroid Abnormalities: </span><span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">Euthyroid goiter</span> and/or <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> (including <span class="product-label-link" type="condition" conceptid="4182596" conceptname="Myxedema">myxedema</span>) accompanied by lower T<span class="Sub">3 </span>and T<span class="Sub">4</span>. Iodine 131 uptake may be elevated. (See <span class="Bold"><a href="#precautions">PRECAUTIONS</a></span>). Paradoxically, rare cases of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span> have been reported.</p>
<p><span class="Italics">EEG Changes: </span>Diffuse slowing, widening of frequency spectrum, potentiation and disorganization of background rhythm.</p>
<p><span class="Italics">EKG Changes: </span>Reversible flattening, isoelectricity or inversion of T-waves.</p>
<p><span class="Italics">Miscellaneous: </span><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, transient scotomata, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, tendency to sleep.</p>
<p><span class="Italics">Miscellaneous Reactions Unrelated to Dosage are: </span>Transient electroencephalographic and electrocardiographic changes, leucocytosis, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, diffuse non-toxic <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">goiter</span> with or without <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, transient <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, generalized pruritis with or without <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, cutaneous <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>, <span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">albuminuria</span>, worsening of <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">organic brain syndromes</span>, excessive <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, edematous <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of ankles or wrists, and <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span> or <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, sometimes resembling <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">diabetes insipidus</span>, and metallic taste.</p>
<p>A single report has been received of the development of painful discoloration of fingers and toes and <span class="product-label-link" type="condition" conceptid="4276665" conceptname="Feels cold">coldness</span> of the extremities within one day of the starting of treatment of lithium. The mechanism through which these symptoms (resembling Raynaud's Syndrome) developed is not known. Recovery followed discontinuance.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">The toxic levels for lithium are close to the therapeutic levels. It is therefore important that patients and their families be cautioned to watch for early symptoms and to discontinue the drug and inform the physician should they occur. Toxic symptoms are listed in detail under <span class="Bold"><a href="#adverse">ADVERSE REACTIONS</a></span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Treatment</h2>
<p class="First">No specific antidote for <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium poisoning</span> is known. Early symptoms of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> can usually be treated by reduction of cessation of dosage of the drug and resumption of the treatment at a lower dose after 24 to 48 hours. In severe cases of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium poisoning</span>, the first and foremost goal of treatment consists of elimination of this ion from the patient.</p>
<p>Treatment is essentially the same as that used in barbiturate <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>: 1) gastric lavage, 2) correction of fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> and 3) regulation of kidney functioning. Urea, mannitol, and aminophylline all produce significant increases in lithium excretion. Hemodialysis is an effective and rapid means of removing the ion from the severely toxic patient. <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> prophylaxis, regular chest X-rays, and preservation of adequate respiration are essential.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="dosageadmin"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Acute Mania</span></h2>
<p class="First">Optimal patient response to Lithium Carbonate usually can be established and maintained with 600 mg t.i.d. Optimal patient response to Lithium Oral Solution usually can be established and maintained with 10 mL (2 full teaspoons) (16 mEq of lithium) t.i.d. Such doses will normally produce an effective serum lithium level ranging between 1.0 and 1.5 mEq/l. Dosage must be individualized according to serum levels and clinical response. Regular monitoring of the patient's clinical state and of serum lithium levels is necessary. Serum levels should be determined twice per week during the acute phase, and until the serum level and clinical condition of the patient have been stabilized.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2>Long-Term Control</h2>
<p class="First">The desirable serum lithium levels are 0.6 to 1.2 mEq/l. Dosage will vary from one individual to another, but usually 300 mg of Lithium Carbonate t.i.d. or q.i.d., or 5 mL (1 full teaspoon) (8 mEq of Lithium) of Lithium Oral Solution t.i.d. or q.i.d. will maintain this level. Serum lithium levels in uncomplicated cases receiving maintenance therapy during remission should be monitored at least every two months.</p>
<p>Patients abnormally sensitive to lithium may exhibit toxic signs at serum levels of 1.0 to 1.5 mEq/l. Elderly patients often respond to reduced dosage, and may exhibit signs of toxicity at serum levels ordinarily tolerated by other patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3"></a><p></p>
<h2>N.B.</h2>
<p class="First">Blood samples for serum lithium determination should be drawn immediately prior to the next dose when lithium concentrations are relatively stable (i.e., 8-12 hours after the previous dose). Total reliance must not be placed on serum levels alone. Accurate patient evaluation requires both clinical and laboratory analysis.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1"></a><p></p>
<p class="First"><span class="Bold">Lithium Oral Solution USP, 8 mEq per 5 mL.</span></p>
<p>NDC 68094-757-62<br>5 mL per unit dose cup<br>Thirty (30) cups per shipper</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.2"></a><p></p>
<h2>Store and Dispense</h2>
<p class="First">Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [see USP Controlled Room Temperature]. Dispense in a tight container as defined in the USP/NF.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<p class="First"><span class="Bold">Manufactured By:<br>Roxane Laboratories, Inc.<br>Columbus, OH 43216</span></p>
<p><span class="Bold">Packaged By:<br>Precision Dose, Inc.<br>South Beloit, IL 61080</span></p>
<p>LI849 Rev. 06/13</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 5 mL Cup Label</h1>
<p class="First"><span class="Bold">NDC 68094-757-59<br>PrecisionDose</span>™</p>
<p><span class="Bold">LITHIUM<br>Oral Solution USP<br>8 mEq per 5 mL</span></p>
<p>Pkg: Precision Dose, Inc., S. Beloit, IL 61080</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 5 mL Cup Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1a04cc23-61fa-455b-9718-2cdcf54036e0&amp;name=lithium-01.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LITHIUM 		
					</strong><br><span class="contentTableReg">lithium carbonate solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68094-757(NDC:0054-3527)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Lithium carbonate</strong> (Lithium Cation) </td>
<td class="formItem">Lithium carbonate</td>
<td class="formItem">300 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>anhydrous citric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium benzoate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sorbitol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">    </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">RASPBERRY</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68094-757-62</td>
<td class="formItem">3  in 1 CASE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68094-757-59</td>
<td class="formItem">5 mL in 1 CUP, UNIT-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA018421</td>
<td class="formItem">10/25/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Precision Dose Inc.
							(035886746)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 12/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>0be4ca00-945d-4c9a-abbe-7e844df508c1</div>
<div>Set id: 1a04cc23-61fa-455b-9718-2cdcf54036e0</div>
<div>Version: 2</div>
<div>Effective Time: 20131226</div>
</div>
</div> <div class="DistributorName">Precision Dose Inc.</div></p>
</body></html>
